Fulltext

Tumor suppressor role of miR-503

Gupta G 1 , Chellappan DK 2 , de Jesus Andreoli Pinto T 3 , Hansbro PM 4 , Bebawy M 5 , Dua K 6

Affiliations 

  • 1 School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, Jaipur, India
  • 2 Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia
  • 3 Department of Pharmacy, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
  • 4 School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, Australia
  • 5 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, Australia
  • 6 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, Australia - kamalpharmacist02@gmail.com
Panminerva Med, 2018 Mar;60(1):17-24.
PMID: 29164842 DOI: 10.23736/S0031-0808.17.03386-9

Abstract

MicroRNAs (miRNAs) are non-coding RNAs of around 20-25 nucleotides in length with highly conserved characteristics. They moderate post-transcriptional silencing by precisely combining with 3' untranslated regions (UTRs) of target mRNAs at a complementary site. miR‑503, an associate of the "canonical" miRNA-16 family, is expressed in numerous types of tumors such as breast cancer, prostate cancer, lung cancer, colorectal cancer, hepatocellular carcinoma, glioblastoma and several others. There is convincing evidence to show that miR‑503 functions as a tumor suppressor gene through its effects on target genes that regulate cell proliferation, migration, and invasion in tumor cells. In this current assessment, we discuss the biology and tumor suppressor role of miR‑503 in different cancers and elaborate on its mechanism of action.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications